Sutro Biopharma, Inc. (STRO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sutro Biopharma, Inc., a Delaware corporation, on April 14, 2025, regarding an event dated April 10, 2025. The Company is headquartered in South San Francisco, California, and its common stock trades on The Nasdaq Global Market under the symbol "STRO."
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the departure of a Board member:
- John Freund, M.D., a member of the Board of Directors since 2014, informed the Board on April 10, 2025, of his decision not to stand for re-election.
- Dr. Freund's term will expire following the Annual Meeting of Shareholders scheduled for June 6, 2025.
- The departure is not due to any disagreement with the Company regarding operations, policies, or practices.
- Dr. Freund will continue to advise the Company's management in a consultant capacity.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, outlook, or management commentary on business strategy. No new risks, contingencies, or unusual items were disclosed in this report.
Key Facts for Investor Verification
- Verify the composition of the Board of Directors following the June 6, 2025, Annual Meeting of Shareholders.
- Confirm the terms of Dr. Freund's ongoing consulting arrangement with the Company.
- Review the Company's most recent 10-K or 10-Q filings for current financial status, as this 8-K contains no financial data.